Literature DB >> 16958605

Analysis of protein S-100B in serum: a methodological study.

Kay Müller1, Astrid Elverland, Bertil Romner, Knut Waterloo, Bodil Langbakk, Johan Undén, Tor Ingebrigtsen.   

Abstract

BACKGROUND: Dysfunction and damage of the human central nervous system can be detected with biochemical markers, and protein S-100B is the best-established such marker. The aim of this study was to evaluate whether the protein is stable during long-term storage, to establish reference values for the new Elecsys S100 test and to compare this new method with the Liaison Sangtec 100 test.
METHODS: We analysed blood samples from 118 blood donors and 196 patients with subarachnoid haemorrhage or head injury. The long-term stability of S-100B in frozen serum samples was evaluated with repeated analysis in 1997 and 2003 using an immunoradiometric assay. Method comparison between the Liaison Sangtec 100 and Elecsys S100 tests was performed using Bland-Altman difference plots.
RESULTS: Serum concentrations increased significantly during long-term storage (mean difference 0.15 microg/L; +/-2 SD, 0.55 microg/L). Serum measurements using the Elecsys S100 method in 118 healthy blood donors showed S-100B levels between 0.02 and 0.08 microg/L (mean 0.05). The 95th percentile was 0.07 microg/L. The Liaison Sangtec 100 test usually measured higher concentrations than the Elecsys S100 method, and the difference between the two methods increased with increasing concentrations. The mean difference between the methods was 0.14 microg/L (+/-2 SD, 0.39 microg/L).
CONCLUSIONS: Protein S-100B is not stable during long-term storage and the two analytical methods are not interchangeable.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16958605     DOI: 10.1515/CCLM.2006.211

Source DB:  PubMed          Journal:  Clin Chem Lab Med        ISSN: 1434-6621            Impact factor:   3.694


  13 in total

1.  Acute phase response after fatal traumatic brain injury.

Authors:  Benjamin Ondruschka; Sandra Schuch; Dirk Pohlers; Heike Franke; Jan Dreßler
Journal:  Int J Legal Med       Date:  2018-01-06       Impact factor: 2.686

2.  Raising the Bar for Traumatic Brain Injury Biomarker Research: Methods Make a Difference.

Authors:  Linda Papa; Kevin K W Wang
Journal:  J Neurotrauma       Date:  2017-04-26       Impact factor: 5.269

Review 3.  Potential Blood-based Biomarkers for Concussion.

Authors:  Linda Papa
Journal:  Sports Med Arthrosc Rev       Date:  2016-09       Impact factor: 1.985

Review 4.  A systematic review of the biomarker S100B: implications for sport-related concussion management.

Authors:  Stefanie Schulte; Leslie W Podlog; J Jordan Hamson-Utley; Frederick G Strathmann; Heiko K Strüder
Journal:  J Athl Train       Date:  2014 Nov-Dec       Impact factor: 2.860

5.  Prognostic value of serum s100 protein by elecsys s100 immunoassay in patients with spontaneous subarachnoid and intracerebral hemorrhages.

Authors:  Seok-Mann Yoon; Young-Jin Choi; Hwi-Jun Kim; Jai-Joon Shim; Hack-Gun Bae; Il-Gyu Yun
Journal:  J Korean Neurosurg Soc       Date:  2008-11-30

6.  Secondary peaks of S100B in serum relate to subsequent radiological pathology in traumatic brain injury.

Authors:  Eric P Thelin; David W Nelson; Bo-Michael Bellander
Journal:  Neurocrit Care       Date:  2014-04       Impact factor: 3.210

7.  S100B levels are affected by older age but not by alcohol intoxication following mild traumatic brain injury.

Authors:  Olga Calcagnile; Anders Holmén; Michelle Chew; Johan Undén
Journal:  Scand J Trauma Resusc Emerg Med       Date:  2013-07-06       Impact factor: 2.953

Review 8.  Biomarkers of Traumatic Brain Injury: Temporal Changes in Body Fluids.

Authors:  Harel Adrian; Kvist Mårten; Nuutinen Salla; Välimaa Lasse
Journal:  eNeuro       Date:  2016-12-21

9.  Clinical validation of S100B use in management of mild head injury.

Authors:  Olga Calcagnile; Linda Undén; Johan Undén
Journal:  BMC Emerg Med       Date:  2012-10-27

10.  Kinetic modelling of serum S100b after traumatic brain injury.

Authors:  A Ercole; E P Thelin; A Holst; B M Bellander; D W Nelson
Journal:  BMC Neurol       Date:  2016-06-17       Impact factor: 2.474

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.